A crucial second pivotal trial in uterine fibroids fails to dispel concerns about the company’s linzagolix.
Daridorexant can't reach the heights of its first pivotal study win, but a pooled analysis could still save it.
The implosion of Zygel’s fragile X study leaves its developer few places to turn.
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
SGLT2 inhibitors primarily treat diabetes, with benefits also seen in heart and kidney diseases. Might they also help prevent diabetes in the first place?
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
The rivals have taken different strategies with next-gen pneumococcal vaccines, which will be fighting for a blockbuster market that is Pfizer’s to lose.
Biogen’s aducanumab filing is keenly awaited, as are clinical data from Sanofi, Bristol Myers Squibb, Lilly and others.
Roche’s Akt inhibitor’s first pivotal result, in first-line prostate cancer, is at best a partial success and at worst an irrelevance.